Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease
The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI...
Saved in:
| Published in | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 19; no. 4; pp. 691 - 697 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Tokyo
Elsevier Ltd
01.08.2013
Springer Japan |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1341-321X 1437-7780 1437-7780 |
| DOI | 10.1007/s10156-012-0545-x |
Cover
| Abstract | The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4–38 days). In proven and probable diagnosis patients (n=5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-d-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. |
|---|---|
| AbstractList | The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4–38 days). In proven and probable diagnosis patients (
n
= 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-
d
-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum
Aspergillus
galactomannan antigen levels decreased in 3 of 4 patients with
Aspergillus
infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4a38 days). In proven and probable diagnosis patients (n = 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-I2-d-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4–38 days). In proven and probable diagnosis patients (n=5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-d-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4-38 days). In proven and probable diagnosis patients (n = 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-D-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. Abstract The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4–38 days). In proven and probable diagnosis patients ( n = 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β- d -glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4-38 days). In proven and probable diagnosis patients (n = 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-D-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs.The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4-38 days). In proven and probable diagnosis patients (n = 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-D-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs. |
| Author | Kotani, Takuya Nagai, Koji Hanafusa, Toshiaki Makino, Shigeki Yoshida, Shuzo Isoda, Kentaro Takeuchi, Tohru Hata, Kenichiro Wakura, Daisuke |
| Author_xml | – sequence: 1 givenname: Takuya surname: Kotani fullname: Kotani, Takuya – sequence: 2 givenname: Tohru surname: Takeuchi fullname: Takeuchi, Tohru email: t-takeuchi@poh.osaka-med.ac.jp – sequence: 3 givenname: Shigeki surname: Makino fullname: Makino, Shigeki – sequence: 4 givenname: Kenichiro surname: Hata fullname: Hata, Kenichiro – sequence: 5 givenname: Shuzo surname: Yoshida fullname: Yoshida, Shuzo – sequence: 6 givenname: Koji surname: Nagai fullname: Nagai, Koji – sequence: 7 givenname: Daisuke surname: Wakura fullname: Wakura, Daisuke – sequence: 8 givenname: Kentaro surname: Isoda fullname: Isoda, Kentaro – sequence: 9 givenname: Toshiaki surname: Hanafusa fullname: Hanafusa, Toshiaki |
| BackLink | https://cir.nii.ac.jp/crid/1573668925937514368$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/23325065$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1rFTEUhgep2A_9AW4kCxduRvMxSSYIgpb6AQUXKrgLucmJTTuTjMnc2vvvzTAtQsHbTRLC-7zncN5z3BzEFKFpnhP8mmAs3xSCCRctJrTFvOPtzaPmiHRMtlL2-KC-WUdaRsnPw-a4lEuMieR9_6Q5pIxRjgU_aq7OvA_W2B0y0aFiPMw7lDwawpRKGs2AzDhdpBlysCGiD8injBzAhMadTSUUVH8nMweIc0F_wnyBbIoR7ByuAc2hlC0gFwqYAk-bx94MBZ7d3ifNj49n308_t-dfP305fX_eWt7LuWXKKuc3XnC86ZVjyrCNpx5ET7nknZNCCNMT5YE6hTl1mPqNMspwSUiPBTtpXq2-U06_t1BmPYZiYRhMhLQtmnDMGRWq7x6WdkSxrqOCVOmLW-l2M4LTUw6jyTt9N8sqkKvA5lRKBq9tmOtkUpyzCYMmWC-p6TU1XVPTS2r6ppLkHnlnvo-hK1OqNv6CrC_TNsc6173QyxWKIdTulpNwyYToFeWKSV63R_RV9naVQU3pOlTvYmvAFlzINVntUthb5N092g61lDXDFeyg_GtTl8rob8uWLktKmMTVcglF_d_ggeJ_AUlz7uE |
| CitedBy_id | crossref_primary_10_1177_0961203318817118 crossref_primary_10_3389_fmolb_2024_1405383 crossref_primary_10_3762_bjnano_15_30 crossref_primary_10_1111_ijd_13497 |
| Cites_doi | 10.1046/j.1439-0507.2000.00563.x 10.1002/acr.20001 10.1007/s10067-006-0319-x 10.1007/s10156-008-0617-0 10.1136/ard.60.12.1141 10.1086/588660 10.1007/s00134-003-1867-z 10.1086/597395 10.1093/cid/cir073 10.1086/514341 10.1086/496927 10.1007/s10096-004-1185-6 10.1086/525258 10.1128/JCM.39.3.954-958.2001 10.1186/1471-2334-10-239 10.1007/s100960000334 10.1136/jcp.2004.016287 10.1007/s10165-006-0493-3 10.1086/596757 10.1007/s10156-009-0689-5 10.1093/jac/49.suppl_1.21 10.3109/s10165-006-0493-3 10.3314/jjmm.34.311 10.2336/nishinihonhifu.66.29 |
| ContentType | Journal Article |
| Copyright | 2013 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2013 |
| Copyright_xml | – notice: 2013 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases – notice: Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases – notice: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2013 |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 M7N |
| DOI | 10.1007/s10156-012-0545-x |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Algology Mycology and Protozoology Abstracts (Microbiology C) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Algology Mycology and Protozoology Abstracts (Microbiology C) |
| DatabaseTitleList | Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology Medicine |
| EISSN | 1437-7780 |
| EndPage | 697 |
| ExternalDocumentID | 23325065 10_1007_s10156_012_0545_x 10031194398 S1341321X13701004 1_s2_0_S1341321X13701004 |
| Genre | Journal Article |
| GroupedDBID | --- --M -Y2 -~C .1- .55 .86 .FO .~1 0R~ 0VY 1N0 1P~ 1SB 1~. 2.D 28- 29K 2JY 2P1 2VQ 2~H 30V 4.4 408 409 40D 457 4G. 53G 5GY 5QI 5VS 67Z 6NX 7-5 8P~ 8TC 8UJ 95. 95~ AAAJQ AAEDT AAEDW AAIAL AAIKJ AAKOC AALRI AANXM AAOAW AAQFI AARHV AATTM AAXKI AAXUO AAYWO ABFSG ABJNI ABMAC ABMNI ABMZM ABQSL ABXDB ACDAQ ACGFS ACIEU ACLOT ACOMO ACRLP ACSTC ACVFH ADBBV ADCNI ADEZE ADHKG ADIMF ADKPE ADQRH ADRFC ADVLN AEBSH AEFIE AEIPS AEKER AENEX AEUPX AEVXI AEZWR AFBBN AFEXP AFHIU AFLOW AFPUW AFRHN AFTJW AFWTZ AFXIZ AGGDS AGHFR AGJBK AGQPQ AGUBO AHBYD AHKAY AHSBF AHWEU AIEXJ AIGII AIIUN AIKHN AITUG AIXLP AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMKLP AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN BA0 BBWZM BGNMA BKOJK BLXMC BNPGV CAG CJTIS COF CS3 CSCUP D-I DL5 EBS EFJIC EFKBS EFLBG EJD EMOBN EN4 F5P FDB FEDTE FIRID FYGXN GBLVA GQ8 GXS H13 HF~ HG5 HG6 HMJXF HVGLF HZ~ I09 IHE IXC IXE IZIGR IZQ I~X KDC KOM KOW KPH LAS M41 M4Y MA- MO0 N2Q N9A NB0 NDZJH NU0 O9- O93 O9G O9I OAM OAUVE OC~ P-8 P-9 P19 P2P P9S PC. PT5 QOK QOS R4E R89 R9I RNI ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SDE SDH SDM SMD SOJ SPCBC SSH SSI SSZ SV3 T13 T16 T5K TSK TSV TT1 TUC U2A VC2 WJK WK8 X7M Z45 Z5R ~A9 ~EX ~G- -5E -5G -BR 0SF AACTN AAYZH ABTEG ADINQ AFCTW AFKWA AJOXV AMFUW GQ6 NCXOZ RIG SZN Z7U Z82 Z87 Z8O Z8V Z91 AAIAV ABLVK ABYKQ AFNRJ AHPSJ AJBFU AGCQF AGRNS RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 M7N |
| ID | FETCH-LOGICAL-c587t-39c9dfbf650b89d39a3bf2fe6825754d7666a819fe2d9052d02fb9a9a57118063 |
| IEDL.DBID | .~1 |
| ISSN | 1341-321X 1437-7780 |
| IngestDate | Sat Sep 27 17:09:11 EDT 2025 Wed Oct 01 13:48:44 EDT 2025 Wed Feb 19 02:43:27 EST 2025 Thu Apr 24 23:03:44 EDT 2025 Wed Oct 29 21:48:58 EDT 2025 Fri Feb 21 02:33:32 EST 2025 Thu Jun 26 21:25:58 EDT 2025 Fri Feb 23 02:29:20 EST 2024 Sun Feb 23 10:18:49 EST 2025 Tue Oct 14 19:28:31 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Connective tissue disease Preemptive treatment Invasive fungal infection Liposomal amphotericin B |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c587t-39c9dfbf650b89d39a3bf2fe6825754d7666a819fe2d9052d02fb9a9a57118063 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| ORCID | 0000-0003-2190-0780 |
| PMID | 23325065 |
| PQID | 1419344261 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1505326984 proquest_miscellaneous_1419344261 pubmed_primary_23325065 crossref_citationtrail_10_1007_s10156_012_0545_x crossref_primary_10_1007_s10156_012_0545_x springer_journals_10_1007_s10156_012_0545_x nii_cinii_1573668925937514368 elsevier_sciencedirect_doi_10_1007_s10156_012_0545_x elsevier_clinicalkeyesjournals_1_s2_0_S1341321X13701004 elsevier_clinicalkey_doi_10_1007_s10156_012_0545_x |
| PublicationCentury | 2000 |
| PublicationDate | 2013-08-01 |
| PublicationDateYYYYMMDD | 2013-08-01 |
| PublicationDate_xml | – month: 08 year: 2013 text: 2013-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Netherlands |
| PublicationSubtitle | Official Journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases |
| PublicationTitle | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| PublicationTitleAbbrev | J Infect Chemother |
| PublicationTitleAlternate | J Infect Chemother |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Springer Japan |
| Publisher_xml | – name: Elsevier Ltd – name: Springer Japan |
| References | Arend, Kuijper, Allaart, Muller, Dissel (bib0115) 2004; 23 Wilson, Sewell, Mowad (bib0110) 2008; 7 Mehta, Hashkes, Avery, Deal (bib0130) 2010; 62 Adler-Moore (bib0035) 1994; 14 Noël, Lortholary, Casassus, Cohen, Généreau, André (bib0005) 2001; 60 Cordonnier, Pautas, Maury, Vekhoff, Farhat, Suarez (bib0060) 2009; 48 Shimizu, Miyashita, Obase, Sugiu, Ohue, Mouri (bib0100) 2008; 14 Karino, Osaki, Kanamori, Yahata (bib0070) 2010; 48 Hirano, Hashimoto, Hirose, Mori (bib0015) 1993; 34 Aikawa, Kusachi, Oda, Takesue, Tanaka (bib0065) 2009; 15 Pappas, Kauffman, Andes, Benjamin, Calandra, Edwards (bib0045) 2009; 48 Quindós, Carrillo-Muñoz, Ruesga, Alonso-Vargas, Miranda, Tur-Tur (bib0025) 2000; 19 Winne, Praet, Brusselle, Veys, Mielants (bib0080) 2007; 26 Oda, Fujinaga, Takahashi (bib0120) 2006; 16 Maertens, Theunissen, Verhoef, Verschakelen, Lagrou, Verbeken (bib0055) 2005; 41 Adler-Moore, Proffitt (bib0030) 2002; 49 Yoshida (bib0010) 2004; 31 Abe, Wakamatsu, Tanabe, Mochizuki, Yanagihara, Ishizaki (bib0075) 2004; 66 Espinel-Ingroff (bib0020) 2011; 39 Romano, Castelli, Laurini, Massai (bib0105) 2000; 43 De Pauw, Walsh, Donnelly, Stevens, Edwards, Calandra (bib0050) 2008; 46 True, Penmetcha, Peckham (bib0090) 2002; 29 Thomas, Munuswamy, Adu-Poku, Holgate, Hickling, Lambert (bib0125) 2005; 58 Probst, Pongratz, Capellino, Szeimies, Schölmerich, Fleck (bib0085) 2010; 10 Freifeld, Bow, Sepkowitz, Boeckh, Ito, Mullen (bib0135) 2011; 52 Walsh, Anaissie, Denning, Herbrecht, Kontoyiannis, Marr (bib0040) 2008; 46 Cornely, Maertens, Bresnik, Ebrahimi, Ullmann, Bouza (bib0140) 2007; 44 van der Klooster, Bosman, Oudemans-van Straaten, Spoel, Wester, Zandstra (bib0095) 2003; 29 Noël, Lortholary, Casassus, Cohen, Généreau, André (CR1) 2001; 60 Quindós, Carrillo-Muñoz, Ruesga, Alonso-Vargas, Miranda, Tur-Tur (CR5) 2000; 19 Cornely, Maertens, Bresnik, Ebrahimi, Ullmann, Bouza (CR28) 2007; 44 Maertens, Theunissen, Verhoef, Verschakelen, Lagrou, Verbeken (CR11) 2005; 41 Yoshida (CR2) 2004; 31 van der Klooster, Bosman, Oudemans-van Straaten, van der Spoel, Wester, Zandstra (CR19) 2003; 29 Shimizu, Miyashita, Obase, Sugiu, Ohue, Mouri (CR20) 2008; 14 Pappas, Kauffman, Andes, Benjamin, Calandra, Edwards (CR9) 2009; 48 Probst, Pongratz, Capellino, Szeimies, Schölmerich, Fleck (CR17) 2010; 10 Freifeld, Bow, Sepkowitz, Boeckh, Ito, Mullen (CR27) 2011; 52 Thomas, Munuswamy, Adu-Poku, Holgate, Hickling, Lambert (CR25) 2005; 58 Karino, Osaki, Kanamori, Yahata (CR14) 2010; 48 Walsh, Anaissie, Denning, Herbrecht, Kontoyiannis, Marr (CR8) 2008; 46 True, Penmetcha, Peckham (CR18) 2002; 29 Aikawa, Kusachi, Oda, Takesue, Tanaka (CR13) 2009; 15 Arend, Kuijper, Allaart, Muller, Van Dissel (CR23) 2004; 23 Oda, Fujinaga, Takahashi (CR24) 2006; 16 Espinel-Ingroff (CR4) 2011; 39 De Pauw, Walsh, Donnelly, Stevens, Edwards, Calandra (CR10) 2008; 46 Winne, Praet, Brusselle, Veys, Mielants (CR16) 2007; 26 Wilson, Sewell, Mowad (CR22) 2008; 7 Hirano, Hashimoto, Hirose, Mori (CR3) 1993; 34 Romano, Castelli, Laurini, Massai (CR21) 2000; 43 Adler-Moore (CR7) 1994; 14 Adler-Moore, Proffitt (CR6) 2002; 49 Abe, Wakamatsu, Tanabe, Mochizuki, Yanagihara, Ishizaki (CR15) 2004; 66 Mehta, Hashkes, Avery, Deal (CR26) 2010; 62 Cordonnier, Pautas, Maury, Vekhoff, Farhat, Suarez (CR12) 2009; 48 Shimizu (10.1007/s10156-012-0545-x_bib0100) 2008; 14 Romano (10.1007/s10156-012-0545-x_bib0105) 2000; 43 Adler-Moore (10.1007/s10156-012-0545-x_bib0030) 2002; 49 Quindós (10.1007/s10156-012-0545-x_bib0025) 2000; 19 Maertens (10.1007/s10156-012-0545-x_bib0055) 2005; 41 Oda (10.1007/s10156-012-0545-x_bib0120) 2006; 16 Wilson (10.1007/s10156-012-0545-x_bib0110) 2008; 7 Cordonnier (10.1007/s10156-012-0545-x_bib0060) 2009; 48 Aikawa (10.1007/s10156-012-0545-x_bib0065) 2009; 15 Espinel-Ingroff (10.1007/s10156-012-0545-x_bib0020) 2011; 39 Walsh (10.1007/s10156-012-0545-x_bib0040) 2008; 46 True (10.1007/s10156-012-0545-x_bib0090) 2002; 29 Pappas (10.1007/s10156-012-0545-x_bib0045) 2009; 48 Cornely (10.1007/s10156-012-0545-x_bib0140) 2007; 44 Adler-Moore (10.1007/s10156-012-0545-x_bib0035) 1994; 14 Freifeld (10.1007/s10156-012-0545-x_bib0135) 2011; 52 Winne (10.1007/s10156-012-0545-x_bib0080) 2007; 26 Mehta (10.1007/s10156-012-0545-x_bib0130) 2010; 62 Abe (10.1007/s10156-012-0545-x_bib0075) 2004; 66 Yoshida (10.1007/s10156-012-0545-x_bib0010) 2004; 31 Thomas (10.1007/s10156-012-0545-x_bib0125) 2005; 58 Probst (10.1007/s10156-012-0545-x_bib0085) 2010; 10 De Pauw (10.1007/s10156-012-0545-x_bib0050) 2008; 46 Hirano (10.1007/s10156-012-0545-x_bib0015) 1993; 34 Noël (10.1007/s10156-012-0545-x_bib0005) 2001; 60 Karino (10.1007/s10156-012-0545-x_bib0070) 2010; 48 Arend (10.1007/s10156-012-0545-x_bib0115) 2004; 23 van der Klooster (10.1007/s10156-012-0545-x_bib0095) 2003; 29 |
| References_xml | – volume: 14 start-page: 315 year: 2008 end-page: 318 ident: bib0100 article-title: An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow publication-title: J Infect Chemother – volume: 52 start-page: e56 year: 2011 end-page: e93 ident: bib0135 article-title: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America publication-title: Clin Infect Dis – volume: 44 start-page: 1289 year: 2007 end-page: 1297 ident: bib0140 article-title: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) publication-title: Clin Infect Dis – volume: 62 start-page: 575 year: 2010 end-page: 579 ident: bib0130 article-title: A 21-year-old man with Still’s disease with fever, rash, and pancytopenia publication-title: Arthritis Care Res – volume: 48 start-page: 503 year: 2009 end-page: 535 ident: bib0045 article-title: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America publication-title: Clin Infect Dis – volume: 29 start-page: 1561 year: 2002 end-page: 1563 ident: bib0090 article-title: Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab publication-title: J Rheumatol – volume: 49 start-page: 21 year: 2002 end-page: 30 ident: bib0030 article-title: AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience publication-title: J Antimicrob Chemother – volume: 46 start-page: 1813 year: 2008 end-page: 1821 ident: bib0050 article-title: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group publication-title: Clin Infect Dis – volume: 15 start-page: 219 year: 2009 end-page: 227 ident: bib0065 article-title: Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm publication-title: J Infect Chemother – volume: 7 start-page: 53 year: 2008 end-page: 54 ident: bib0110 article-title: Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab publication-title: J Drugs Dermatol – volume: 31 start-page: 75 year: 2004 end-page: 81 ident: bib0010 article-title: Efficacy of anti-β-glucan antibody in early diagnosis and treatment of opportunistic infections on immunosuppressive therapy in ANCA associated vasculitis publication-title: Rheumatology (Tokyo) – volume: 43 start-page: 151 year: 2000 end-page: 154 ident: bib0105 article-title: Case report. Primary cutaneous histoplasmosis in an immunosuppressed patient publication-title: Mycoses – volume: 41 start-page: 1242 year: 2005 end-page: 1250 ident: bib0055 article-title: Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study publication-title: Clin Infect Dis – volume: 66 start-page: 29 year: 2004 end-page: 33 ident: bib0075 article-title: A case of cutaneous cryptococcosis associated with rheumatoid arthritis publication-title: Nishinihon Hifuka – volume: 39 start-page: 954 year: 2011 end-page: 958 ident: bib0020 article-title: In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi publication-title: J Clin Microbiol – volume: 48 start-page: 980 year: 2010 end-page: 984 ident: bib0070 article-title: Case of pulmonary cryptococcosis which developed in a patient receiving abatacept therapy for rheumatoid arthritis publication-title: Nihon Kokyuki Gakkai Zasshi – volume: 48 start-page: 1042 year: 2009 end-page: 1051 ident: bib0060 article-title: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial publication-title: Clin Infect Dis – volume: 23 start-page: 638 year: 2004 end-page: 641 ident: bib0115 article-title: Cavitating pneumonia after treatment with infliximab and prednisone publication-title: Eur J Clin Microbiol Infect Dis – volume: 16 start-page: 260 year: 2006 end-page: 263 ident: bib0120 article-title: Infectious myositis involving the piriformis in a patient with rheumatoid arthritis publication-title: Mod Rheumatol – volume: 29 start-page: 2327 year: 2003 end-page: 2329 ident: bib0095 article-title: Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate publication-title: Intensive Care Med – volume: 46 start-page: 327 year: 2008 end-page: 360 ident: bib0040 article-title: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America publication-title: Clin Infect Dis – volume: 34 start-page: 311 year: 1993 end-page: 316 ident: bib0015 article-title: Clinical aspects of deep mycosis in patients with collagen diseases publication-title: Jpn J Med Mycol – volume: 19 start-page: 645 year: 2000 end-page: 648 ident: bib0025 article-title: In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens publication-title: Eur J Clin Microbiol Infect Dis – volume: 60 start-page: 1141 year: 2001 end-page: 1144 ident: bib0005 article-title: Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus publication-title: Ann Rheum Dis – volume: 58 start-page: 432 year: 2005 end-page: 433 ident: bib0125 article-title: peritonitis in a patient with Felty’s syndrome publication-title: J Clin Pathol – volume: 14 start-page: S3 year: 1994 end-page: S7 ident: bib0035 article-title: AmBisome targeting to fungal infections publication-title: Bone Marrow Transplant – volume: 26 start-page: 1180 year: 2007 end-page: 1182 ident: bib0080 article-title: Bilateral spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules, secondary infected by Aspergillus publication-title: Clin Rheumatol – volume: 10 start-page: 239 year: 2010 ident: bib0085 article-title: Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report publication-title: BMC Infect Dis – volume: 43 start-page: 151 year: 2000 end-page: 154 ident: CR21 article-title: Case report. Primary cutaneous histoplasmosis in an immunosuppressed patient publication-title: Mycoses doi: 10.1046/j.1439-0507.2000.00563.x – volume: 62 start-page: 575 year: 2010 end-page: 579 ident: CR26 article-title: A 21-year-old man with Still’s disease with fever, rash, and pancytopenia publication-title: Arthritis Care Res doi: 10.1002/acr.20001 – volume: 26 start-page: 1180 year: 2007 end-page: 1182 ident: CR16 article-title: Bilateral spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules, secondary infected by Aspergillus publication-title: Clin Rheumatol doi: 10.1007/s10067-006-0319-x – volume: 14 start-page: 315 year: 2008 end-page: 318 ident: CR20 article-title: An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow publication-title: J Infect Chemother doi: 10.1007/s10156-008-0617-0 – volume: 60 start-page: 1141 year: 2001 end-page: 1144 ident: CR1 article-title: Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus publication-title: Ann Rheum Dis doi: 10.1136/ard.60.12.1141 – volume: 46 start-page: 1813 year: 2008 end-page: 1821 ident: CR10 article-title: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group publication-title: Clin Infect Dis doi: 10.1086/588660 – volume: 29 start-page: 2327 year: 2003 end-page: 2329 ident: CR19 article-title: Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate publication-title: Intensive Care Med doi: 10.1007/s00134-003-1867-z – volume: 48 start-page: 1042 year: 2009 end-page: 1051 ident: CR12 article-title: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial publication-title: Clin Infect Dis doi: 10.1086/597395 – volume: 52 start-page: e56 year: 2011 end-page: e93 ident: CR27 article-title: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1093/cid/cir073 – volume: 44 start-page: 1289 year: 2007 end-page: 1297 ident: CR28 article-title: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) publication-title: Clin Infect Dis doi: 10.1086/514341 – volume: 41 start-page: 1242 year: 2005 end-page: 1250 ident: CR11 article-title: Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study publication-title: Clin Infect Dis doi: 10.1086/496927 – volume: 23 start-page: 638 year: 2004 end-page: 641 ident: CR23 article-title: Cavitating pneumonia after treatment with infliximab and prednisone publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-004-1185-6 – volume: 46 start-page: 327 year: 2008 end-page: 360 ident: CR8 article-title: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1086/525258 – volume: 39 start-page: 954 year: 2011 end-page: 958 ident: CR4 article-title: In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi publication-title: J Clin Microbiol doi: 10.1128/JCM.39.3.954-958.2001 – volume: 10 start-page: 239 year: 2010 ident: CR17 article-title: Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report publication-title: BMC Infect Dis doi: 10.1186/1471-2334-10-239 – volume: 31 start-page: 75 year: 2004 end-page: 81 ident: CR2 article-title: Efficacy of anti-β-glucan antibody in early diagnosis and treatment of opportunistic infections on immunosuppressive therapy in ANCA associated vasculitis publication-title: Rheumatology (Tokyo) – volume: 48 start-page: 980 year: 2010 end-page: 4 ident: CR14 article-title: Case of pulmonary cryptococcosis which developed in a patient receiving abatacept therapy for rheumatoid arthritis publication-title: Nihon Kokyuki Gakkai Zasshi – volume: 14 start-page: S3 year: 1994 end-page: S7 ident: CR7 article-title: AmBisome targeting to fungal infections publication-title: Bone Marrow Transplant – volume: 19 start-page: 645 year: 2000 end-page: 648 ident: CR5 article-title: In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s100960000334 – volume: 66 start-page: 29 year: 2004 end-page: 33 ident: CR15 article-title: A case of cutaneous cryptococcosis associated with rheumatoid arthritis publication-title: Nishinihon Hifuka – volume: 58 start-page: 432 year: 2005 end-page: 433 ident: CR25 article-title: peritonitis in a patient with Felty’s syndrome publication-title: J Clin Pathol doi: 10.1136/jcp.2004.016287 – volume: 29 start-page: 1561 year: 2002 end-page: 1563 ident: CR18 article-title: Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab publication-title: J Rheumatol – volume: 16 start-page: 260 year: 2006 end-page: 263 ident: CR24 article-title: Infectious myositis involving the piriformis in a patient with rheumatoid arthritis publication-title: Mod Rheumatol doi: 10.1007/s10165-006-0493-3 – volume: 48 start-page: 503 year: 2009 end-page: 535 ident: CR9 article-title: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1086/596757 – volume: 34 start-page: 311 year: 1993 end-page: 16 ident: CR3 article-title: Clinical aspects of deep mycosis in patients with collagen diseases publication-title: Jpn J Med Mycol – volume: 15 start-page: 219 year: 2009 end-page: 227 ident: CR13 article-title: Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm publication-title: J Infect Chemother doi: 10.1007/s10156-009-0689-5 – volume: 7 start-page: 53 year: 2008 end-page: 54 ident: CR22 article-title: Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab publication-title: J Drugs Dermatol – volume: 49 start-page: 21 year: 2002 end-page: 30 ident: CR6 article-title: AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience publication-title: J Antimicrob Chemother doi: 10.1093/jac/49.suppl_1.21 – volume: 41 start-page: 1242 year: 2005 ident: 10.1007/s10156-012-0545-x_bib0055 article-title: Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study publication-title: Clin Infect Dis doi: 10.1086/496927 – volume: 19 start-page: 645 year: 2000 ident: 10.1007/s10156-012-0545-x_bib0025 article-title: In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s100960000334 – volume: 29 start-page: 2327 year: 2003 ident: 10.1007/s10156-012-0545-x_bib0095 article-title: Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate publication-title: Intensive Care Med doi: 10.1007/s00134-003-1867-z – volume: 49 start-page: 21 year: 2002 ident: 10.1007/s10156-012-0545-x_bib0030 article-title: AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience publication-title: J Antimicrob Chemother doi: 10.1093/jac/49.suppl_1.21 – volume: 7 start-page: 53 year: 2008 ident: 10.1007/s10156-012-0545-x_bib0110 article-title: Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab publication-title: J Drugs Dermatol – volume: 16 start-page: 260 year: 2006 ident: 10.1007/s10156-012-0545-x_bib0120 article-title: Infectious myositis involving the piriformis in a patient with rheumatoid arthritis publication-title: Mod Rheumatol doi: 10.3109/s10165-006-0493-3 – volume: 29 start-page: 1561 year: 2002 ident: 10.1007/s10156-012-0545-x_bib0090 article-title: Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab publication-title: J Rheumatol – volume: 43 start-page: 151 year: 2000 ident: 10.1007/s10156-012-0545-x_bib0105 article-title: Case report. Primary cutaneous histoplasmosis in an immunosuppressed patient publication-title: Mycoses doi: 10.1046/j.1439-0507.2000.00563.x – volume: 44 start-page: 1289 year: 2007 ident: 10.1007/s10156-012-0545-x_bib0140 article-title: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) publication-title: Clin Infect Dis doi: 10.1086/514341 – volume: 46 start-page: 327 year: 2008 ident: 10.1007/s10156-012-0545-x_bib0040 article-title: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1086/525258 – volume: 34 start-page: 311 year: 1993 ident: 10.1007/s10156-012-0545-x_bib0015 article-title: Clinical aspects of deep mycosis in patients with collagen diseases publication-title: Jpn J Med Mycol doi: 10.3314/jjmm.34.311 – volume: 23 start-page: 638 year: 2004 ident: 10.1007/s10156-012-0545-x_bib0115 article-title: Cavitating pneumonia after treatment with infliximab and prednisone publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-004-1185-6 – volume: 60 start-page: 1141 year: 2001 ident: 10.1007/s10156-012-0545-x_bib0005 article-title: Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus publication-title: Ann Rheum Dis doi: 10.1136/ard.60.12.1141 – volume: 14 start-page: 315 year: 2008 ident: 10.1007/s10156-012-0545-x_bib0100 article-title: An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow publication-title: J Infect Chemother doi: 10.1007/s10156-008-0617-0 – volume: 58 start-page: 432 year: 2005 ident: 10.1007/s10156-012-0545-x_bib0125 article-title: Candida albicans peritonitis in a patient with Felty’s syndrome publication-title: J Clin Pathol doi: 10.1136/jcp.2004.016287 – volume: 66 start-page: 29 year: 2004 ident: 10.1007/s10156-012-0545-x_bib0075 article-title: A case of cutaneous cryptococcosis associated with rheumatoid arthritis publication-title: Nishinihon Hifuka doi: 10.2336/nishinihonhifu.66.29 – volume: 39 start-page: 954 year: 2011 ident: 10.1007/s10156-012-0545-x_bib0020 article-title: In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi publication-title: J Clin Microbiol doi: 10.1128/JCM.39.3.954-958.2001 – volume: 31 start-page: 75 year: 2004 ident: 10.1007/s10156-012-0545-x_bib0010 article-title: Efficacy of anti-β-glucan antibody in early diagnosis and treatment of opportunistic infections on immunosuppressive therapy in ANCA associated vasculitis publication-title: Rheumatology (Tokyo) – volume: 46 start-page: 1813 year: 2008 ident: 10.1007/s10156-012-0545-x_bib0050 publication-title: Clin Infect Dis doi: 10.1086/588660 – volume: 62 start-page: 575 year: 2010 ident: 10.1007/s10156-012-0545-x_bib0130 article-title: A 21-year-old man with Still’s disease with fever, rash, and pancytopenia publication-title: Arthritis Care Res doi: 10.1002/acr.20001 – volume: 15 start-page: 219 year: 2009 ident: 10.1007/s10156-012-0545-x_bib0065 article-title: Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm publication-title: J Infect Chemother doi: 10.1007/s10156-009-0689-5 – volume: 48 start-page: 503 year: 2009 ident: 10.1007/s10156-012-0545-x_bib0045 article-title: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1086/596757 – volume: 26 start-page: 1180 year: 2007 ident: 10.1007/s10156-012-0545-x_bib0080 article-title: Bilateral spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules, secondary infected by Aspergillus publication-title: Clin Rheumatol doi: 10.1007/s10067-006-0319-x – volume: 52 start-page: e56 year: 2011 ident: 10.1007/s10156-012-0545-x_bib0135 article-title: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1093/cid/cir073 – volume: 48 start-page: 1042 year: 2009 ident: 10.1007/s10156-012-0545-x_bib0060 article-title: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial publication-title: Clin Infect Dis doi: 10.1086/597395 – volume: 14 start-page: S3 year: 1994 ident: 10.1007/s10156-012-0545-x_bib0035 article-title: AmBisome targeting to fungal infections publication-title: Bone Marrow Transplant – volume: 48 start-page: 980 year: 2010 ident: 10.1007/s10156-012-0545-x_bib0070 article-title: Case of pulmonary cryptococcosis which developed in a patient receiving abatacept therapy for rheumatoid arthritis publication-title: Nihon Kokyuki Gakkai Zasshi – volume: 10 start-page: 239 year: 2010 ident: 10.1007/s10156-012-0545-x_bib0085 article-title: Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report publication-title: BMC Infect Dis doi: 10.1186/1471-2334-10-239 |
| SSID | ssj0017588 |
| Score | 2.005658 |
| Snippet | The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients... Abstract The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for... |
| SourceID | proquest pubmed crossref springer nii elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 691 |
| SubjectTerms | Adult Aged Amphotericin B - adverse effects Amphotericin B - therapeutic use Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Aspergillus Connective tissue disease Connective Tissue Diseases - blood Connective Tissue Diseases - drug therapy Connective Tissue Diseases - microbiology Creatinine - blood Female Hematology, Oncology and Palliative Medicine Humans Infectious Diseases Invasive fungal infection Liposomal amphotericin B Male Medical Microbiology Medicine Medicine & Public Health Middle Aged Mycoses - blood Mycoses - drug therapy Original Article Potassium - blood Preemptive treatment Prognosis Retrospective Studies Treatment Outcome Virology |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZtCqWXkqYvJ01RoeTQRrCWLFs6piUhFFICzcLehGRLsDSxl8qB7r_PjB-7hW425OKDGcmyZ6T5xqP5RMjntPIKvEbFcs89y3gIzIIbYcqnTougC1liNfLFz_x8mv2YydlQxx3H3e5jSrJbqf8pdoNYA0JfzgBmSAbA8ZlENi8w4ik_WaUOAAB39W-wPDPB09mYytzUxX3O6Gk9n2-CnP-lSzsvdLZLXg7wkZ70-n5Fnvh6jzy_GBLke-TosqeiXh7Tq3VlVTymR_RyTVK9fE1-nyJ3BAhSW1c02uDbJW0CvZ4vmtjcwDMs6LlBJmfomX6jAG5p5f2C3izLJs4jhbsDKWuk-DeXlrhnpls-adupkw7ZnzdkenZ69f2cDQcvsFKqomVCl7oKLgB6c0pXQlvhAg8-h3CykFlVQMxjAUoEzys9kbya8OC01VYWyCiXi7dkp25q_55QJa1ygBEAKrjMlQo6dYAyS6mdkJlwCZmMGjDlwEqOh2NcmzWfMirNgNIMKs38TciXVZNFT8mxTZiPajVjrSmsjgYcxrZGxaZGPg7zO5rURBA2v9DK0MhSUUyQey8h2arlAGF6aPLQAw_B4uAD4DWVhchzpSEwFQXi2Vwl5NNoiwamP-Z0bO2bWxhIBgg8wzh4i4zE4z9yrWB473pDXn04LgSA4Fwm5Oto2Wb9lveNd_9R0gfkBe8OEcFtkx_ITvvn1h8ClGvdx27q3gE8bzts priority: 102 providerName: Springer Nature |
| Title | Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X13701004 https://www.clinicalkey.es/playcontent/1-s2.0-S1341321X13701004 https://dx.doi.org/10.1007/s10156-012-0545-x https://cir.nii.ac.jp/crid/1573668925937514368 https://link.springer.com/article/10.1007/s10156-012-0545-x https://www.ncbi.nlm.nih.gov/pubmed/23325065 https://www.proquest.com/docview/1419344261 https://www.proquest.com/docview/1505326984 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals customDbUrl: eissn: 1437-7780 dateEnd: 20161231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: AIKHN dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect customDbUrl: eissn: 1437-7780 dateEnd: 20161231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: ACRLP dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1437-7780 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1437-7780 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017588 issn: 1341-321X databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdd97KXse95W4sGow9btcT6sKTHrLRkGyuFNZA3IdkSmLZ2mFNoXva37-SPhNE2g70EYk6OrDvf_S7S_Q6hD2nhFUSNgmSeesJpCMRCGCHKp06zoKXIYzXyj9NsOuPf5mK-g46GWph4rLL3_Z1Pb711f2XUr-ZoUZajn5GKjNF0njI5TjtOUM5l7GLw-ff6mAdEx7b3ZBQmUXrY2ezK5yB7gWSaEgAugtzcF5seVGV5FwK9tXvaBqWTJ-hxjybxpJvwU7Tjq2fo4Kyjo14d4vNNdVVziA_w2YaoevUcXRxH_ggQxLYqcGODX65wHfBluaib-gpubEHXdWRzzssKf8EAcHHh_QJfrfK6KRsMV3ti1gbHf3RxHs_NtC4UL1uV4n4H6AWanRyfH01J33yB5ELJJWE610VwARCcU7pg2jIXaPAZpJRS8EJC3mMBTgRPCz0WtBjT4LTVVsjIKpexl2i3qiv_GmElrHKAEwAuOO5yBTd1gDRzoR0TnLkEjYdlN3nPTB4bZFyaDady1JQBTZmoKXOToI_rIYuOlmObMB10aYZ6U_CQBoLGtkHyrkG-6d_xxqSmAWFzyw4TxNcj_zLlf_3gHpgZLED8TIVkWaY0JKdMRkybqQS9HwzQgAuI-zq28vU1TIQDCucxF94iI2ILkEwrmN6rznrXC0cZAyCciQR9GszZbJ7yvvm--b_HfIse0bajSDxD-Q7tLn9d-z3AdUu33764--jh5Ov36Sl8m9HJH6QqRaU |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKOcAF8SZAwUioB2jYjR3H9hGqVgu0VSW20t4sO7GliDZZka3UvfDbmcljV6jtInHZQzTOOp7JzDex5xtC3ieFVxA1ijjzzMcpCyG2EEZi5ROnedBS5FiNfHySTc7SbzMx2yL7Qy0MHqvsfX_n01tv3V8Z9as5mpfl6AdSkXGWzBIux0nLCXo3FUxiBvbp9-qcB4THtvkkSscoPmxtdvVzkL5ANs1iQC4ivrotON2pyvImCHpt-7SNSocPyYMeTtLP3YwfkS1fPSa7px0f9XKPTtflVc0e3aWna6bq5RPy8wAJJECQ2qqgjQ1-saR1oOflvG7qC7ixBWXXSOeclxX9QgHh0sL7Ob1Y5nVTNhSu9sysDcVPujTHgzOtD6WLVqe03wJ6Ss4OD6b7k7jvvhDnQslFzHWui-ACQDindMG15S6w4DPIKaVICwmJjwU8ETwr9FiwYsyC01ZbIZFWLuPPyHZVV_4FoUpY5QAoAF5wqcsV3NQB1MyFdlyk3EVkPCy7yXtqcuyQcW7WpMqoKQOaMqgpcxWRD6sh846XY5MwG3RphoJTcJEGosamQfKmQb7pX_LGJKYBYXPNECOSrkb-Zcv_-sMdMDNYAPxNhORZpjRkp1wiqM1URN4NBmjAB-DGjq18fQkTSQGGp5gMb5AR2AMk0wqm97yz3tXCMc4BCWciIh8Hczbrp7xtvi__7zHfknuT6fGROfp68v0Vuc_a9iJ4oPI12V78uvQ7APIW7k37Ev8BKnBGUQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSBMvCMbHAgyMhPYAs9bYcWI_Dlg1PjZVYpX6ZtmxLVVsSYUzif73nPPRItEV8ZKH6Oy4uYvvdz3f7xB6m1onwGtYkjvqSEa9JxrcCBEuNZJ5WfAyViOfX-Rn0-zLjM_6PqdhOO0-pCS7mobI0lQ1xwvrj_8ofIO4A8JgSgBycAIg8l4WeRLAoKf0ZJVGADDc1sLBVk0YTWdDWnPTFLc5prvVfL4Jfv6VOm090vghetBDSXzS6f4RuuOqPbR73ifL99DhpKOlXh7hy3WVVTjCh3iyJqxePkY_TiOPBAhiXVkctHfNEtceX80Xdaiv4RkadF5HVmeYGX_AAHSxdW6Br5dlHeYBw92eoDXg-M8uLuP5mXYrxU2rWtxngp6g6fj08uMZ6ZswkJKLoiFMltJ64wHJGSEtk5oZT73LIbQseGYLiH80wArvqJUjTu2IeiO11LyI7HI5e4p2qrpy-wgLroUBvACwwWSmFDCpAcRZcmkYz5hJ0GjQgCp7hvLYKONKrbmVo9IUKE1FpalfCXq3GrLo6Dm2CdNBrWqoO4WdUoHz2Dao2DTIhf5bDypVAYTV92hl0chSVowiD1-CstXIHs50MOVfDzwAi4MXEK8pL1ieCwlBKisits1Fgt4MtqhgK4j5HV25-gYWkgEaz2JMvEWGx1YguRSwvGedIa9eHGUMAHHOE_R-sGy1_pW3rff5f0m_RruTT2P17fPF1xfoPm17i8TTlC_RTvPzxh0AwmvMq_Yr_g0l1UKU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+liposomal+amphotericin+B+for+deep+mycosis+in+patients+with+connective+tissue+disease&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Kotani%2C+Takuya&rft.au=Takeuchi%2C+Tohru&rft.au=Makino%2C+Shigeki&rft.au=Hata%2C+Kenichiro&rft.date=2013-08-01&rft.issn=1341-321X&rft.volume=19&rft.issue=4&rft.spage=691&rft.epage=697&rft_id=info:doi/10.1007%2Fs10156-012-0545-x&rft.externalDBID=ECK1-s2.0-S1341321X13701004&rft.externalDocID=1_s2_0_S1341321X13701004 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F1341321X%2FS1341321X13X70035%2Fcov150h.gif |